Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-MICRO: Iloprost in Septic Shock
NCT03788837Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2019
- Primary completion
- Jan 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in septic shock comparing intravenous ILOPROST with Intravenous Placebo (2 arms). Primary endpoint: Delta Sequential Organ Failure Assessment Score at Day 7. Started Jul 2019; status: completed.
02
Drugs
iloprost
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT03788837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03788837.